(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...
Stats | |
---|---|
Today's Volume | 58 907.00 |
Average Volume | 114 644 |
Market Cap | 28.24B |
EPS | SEK0 ( 2024-02-14 ) |
Next earnings date | ( SEK0.990 ) 2024-05-07 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | 65.51 |
ATR14 | SEK0.351 (0.07%) |
Volume Correlation
Camurus AB (publ) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Camurus AB (publ) Correlation - Currency/Commodity
Camurus AB (publ) Financials
Annual | 2023 |
Revenue: | SEK1.72B |
Gross Profit: | SEK1.58B (92.06 %) |
EPS: | SEK7.78 |
FY | 2023 |
Revenue: | SEK1.72B |
Gross Profit: | SEK1.58B (92.06 %) |
EPS: | SEK7.78 |
FY | 2022 |
Revenue: | SEK956.34M |
Gross Profit: | SEK853.08M (89.20 %) |
EPS: | SEK1.010 |
FY | 2021 |
Revenue: | SEK600.57M |
Gross Profit: | SEK515.22M (85.79 %) |
EPS: | SEK-1.660 |
Financial Reports:
No articles found.
Camurus AB (publ)
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators